Annual CFO
-$168.88 M
-$119.52 M-242.12%
December 31, 2023
Summary
- As of February 8, 2025, MRSN annual cash flow from operations is -$168.88 million, with the most recent change of -$119.52 million (-242.12%) on December 31, 2023.
- During the last 3 years, MRSN annual CFO has fallen by -$94.19 million (-126.09%).
- MRSN annual CFO is now -634.64% below its all-time high of $31.59 million, reached on December 31, 2016.
Performance
MRSN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$8.58 M
+$13.28 M+60.75%
September 30, 2024
Summary
- As of February 8, 2025, MRSN quarterly cash flow from operations is -$8.58 million, with the most recent change of +$13.28 million (+60.75%) on September 30, 2024.
- Over the past year, MRSN quarterly CFO has increased by +$37.50 million (+81.39%).
- MRSN quarterly CFO is now -115.71% below its all-time high of $54.60 million, reached on September 30, 2022.
Performance
MRSN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$95.05 M
+$37.50 M+28.29%
September 30, 2024
Summary
- As of February 8, 2025, MRSN TTM cash flow from operations is -$95.05 million, with the most recent change of +$37.50 million (+28.29%) on September 30, 2024.
- Over the past year, MRSN TTM CFO has increased by +$93.10 million (+49.48%).
- MRSN TTM CFO is now -396.38% below its all-time high of $32.07 million, reached on March 31, 2016.
Performance
MRSN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
MRSN Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -242.1% | +81.4% | +49.5% |
3 y3 years | -126.1% | +81.4% | +49.5% |
5 y5 years | -205.9% | +81.4% | +49.5% |
MRSN Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -242.1% | at low | -115.7% | +86.1% | -134.5% | +49.5% |
5 y | 5-year | -242.1% | at low | -115.7% | +86.1% | -134.5% | +49.5% |
alltime | all time | -634.6% | at low | -115.7% | +86.1% | -396.4% | +49.5% |
Mersana Therapeutics Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$8.58 M(-60.8%) | -$95.05 M(-28.3%) |
Jun 2024 | - | -$21.86 M(-33.1%) | -$132.56 M(-23.2%) |
Mar 2024 | - | -$32.66 M(+2.2%) | -$172.53 M(+2.2%) |
Dec 2023 | -$168.88 M(+242.1%) | -$31.96 M(-30.6%) | -$168.88 M(-10.2%) |
Sep 2023 | - | -$46.08 M(-25.5%) | -$188.15 M(+115.1%) |
Jun 2023 | - | -$61.83 M(+113.2%) | -$87.47 M(+24.2%) |
Mar 2023 | - | -$29.00 M(-43.4%) | -$70.41 M(+42.6%) |
Dec 2022 | -$49.36 M(-64.7%) | -$51.23 M(-193.8%) | -$49.36 M(+21.8%) |
Sep 2022 | - | $54.60 M(-221.9%) | -$40.53 M(-69.1%) |
Jun 2022 | - | -$44.78 M(+462.9%) | -$131.23 M(+8.5%) |
Mar 2022 | - | -$7.96 M(-81.2%) | -$120.92 M(-13.6%) |
Dec 2021 | -$139.99 M(+87.4%) | -$42.40 M(+17.5%) | -$139.99 M(+21.8%) |
Sep 2021 | - | -$36.10 M(+4.7%) | -$114.91 M(+16.1%) |
Jun 2021 | - | -$34.47 M(+27.6%) | -$99.00 M(+23.0%) |
Mar 2021 | - | -$27.02 M(+56.0%) | -$80.47 M(+7.7%) |
Dec 2020 | -$74.70 M | -$17.32 M(-14.2%) | -$74.70 M(+6.8%) |
Sep 2020 | - | -$20.20 M(+26.7%) | -$69.95 M(+5.9%) |
Jun 2020 | - | -$15.94 M(-25.0%) | -$66.04 M(+2.7%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2020 | - | -$21.25 M(+68.9%) | -$64.30 M(-5.1%) |
Dec 2019 | -$67.74 M(+22.7%) | -$12.58 M(-22.8%) | -$67.74 M(-4.7%) |
Sep 2019 | - | -$16.28 M(+14.7%) | -$71.07 M(+8.9%) |
Jun 2019 | - | -$14.20 M(-42.5%) | -$65.26 M(+4.4%) |
Mar 2019 | - | -$24.69 M(+55.2%) | -$62.51 M(+13.2%) |
Dec 2018 | -$55.22 M(+29.4%) | -$15.90 M(+51.8%) | -$55.22 M(+9.8%) |
Sep 2018 | - | -$10.47 M(-8.5%) | -$50.31 M(-1.2%) |
Jun 2018 | - | -$11.45 M(-34.2%) | -$50.92 M(+3.6%) |
Mar 2018 | - | -$17.39 M(+58.1%) | -$49.16 M(+15.2%) |
Dec 2017 | -$42.68 M(-235.1%) | -$11.00 M(-0.8%) | -$42.68 M(+130.6%) |
Sep 2017 | - | -$11.08 M(+14.4%) | -$18.51 M(+51.7%) |
Jun 2017 | - | -$9.69 M(-11.2%) | -$12.20 M(+7.1%) |
Mar 2017 | - | -$10.91 M(-182.8%) | -$11.39 M(-136.1%) |
Dec 2016 | $31.59 M(-427.8%) | $13.18 M(-375.9%) | $31.59 M(+71.6%) |
Sep 2016 | - | -$4.78 M(-46.2%) | $18.41 M(-20.6%) |
Jun 2016 | - | -$8.88 M(-127.7%) | $23.19 M(-27.7%) |
Mar 2016 | - | $32.07 M | $32.07 M |
Dec 2015 | -$9.64 M | - | - |
FAQ
- What is Mersana Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Mersana Therapeutics?
- What is Mersana Therapeutics annual CFO year-on-year change?
- What is Mersana Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly CFO year-on-year change?
- What is Mersana Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Mersana Therapeutics?
- What is Mersana Therapeutics TTM CFO year-on-year change?
What is Mersana Therapeutics annual cash flow from operations?
The current annual CFO of MRSN is -$168.88 M
What is the all time high annual CFO for Mersana Therapeutics?
Mersana Therapeutics all-time high annual cash flow from operations is $31.59 M
What is Mersana Therapeutics annual CFO year-on-year change?
Over the past year, MRSN annual cash flow from operations has changed by -$119.52 M (-242.12%)
What is Mersana Therapeutics quarterly cash flow from operations?
The current quarterly CFO of MRSN is -$8.58 M
What is the all time high quarterly CFO for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly cash flow from operations is $54.60 M
What is Mersana Therapeutics quarterly CFO year-on-year change?
Over the past year, MRSN quarterly cash flow from operations has changed by +$37.50 M (+81.39%)
What is Mersana Therapeutics TTM cash flow from operations?
The current TTM CFO of MRSN is -$95.05 M
What is the all time high TTM CFO for Mersana Therapeutics?
Mersana Therapeutics all-time high TTM cash flow from operations is $32.07 M
What is Mersana Therapeutics TTM CFO year-on-year change?
Over the past year, MRSN TTM cash flow from operations has changed by +$93.10 M (+49.48%)